Skip to main content

Dr. Tim A. Richardson, MD

Urology (Urology Physician)

  • Medicare participating

At a glance

Years since graduation
24
In the NPI registry since
2007
Medicare patients seen, 2024
1,497

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2002Medical school: University of Kansas School of Med (Kc/Wich/Sal)
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Urology Physician primary
    KS license 04-35760

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Urology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,497
Services billed
25,582
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, denosumab, 1 mg10,32069
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml7,14167
Established patient office or other outpatient visit, 30-39 minutes856576
Bcg live intravesical instillation, 1 mg66712
Leuprolide acetate (for depot suspension), 7.5 mg64597
Insertion of needle into vein for collection of blood sample269256
New patient office or other outpatient visit, 45-59 minutes268268
Manual urinalysis test with examination using microscope, automated234208
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle224103
Diagnostic exam of bladder and urethra using an endoscope222196

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Tamsulosin Hcl
Other prescribers in Wichita, KS
850
Erleada (apalutamide)365
Orgovyx (relugolix)361
Finasteride
Other prescribers in Wichita, KS
277
Xtandi (enzalutamide)242
Nubeqa (darolutamide)218
Myrbetriq (mirabegron)
Other prescribers in Wichita, KS
170
Hydrocodone-Acetaminophen (hydrocodone/acetaminophen)
Other prescribers in Wichita, KS
142
Solifenacin Succinate
Other prescribers in Wichita, KS
99
Prednisone
Other prescribers in Wichita, KS
87

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 94 payments worth $57,472 in total to this clinician.

By company
Janssen Biotech, Inc.$20,383
Astellas Pharma US Inc$8,245
Pfizer Inc.$5,623
Merck Sharp & Dohme LLC$5,282
Bayer HealthCare Pharmaceuticals Inc.$4,691
Dendreon Pharmaceuticals LLC$3,864
Ferring Pharmaceuticals Inc.$2,850
Immunitybio, Inc.$2,779
By type
Compensation for services other than consulting (speaking, faculty)$31,623
Consulting Fee$19,160
Honoraria$2,500
Food and Beverage$2,410
Travel and Lodging$1,780

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 5, 2025Astellas Pharma US Inc
Nov 5, 2025
Consulting Fee
Xtandi · Oncology
$5,000
Dec 17, 2025Merck Sharp & Dohme LLC
Dec 17, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$4,770
Oct 23, 2025Janssen Biotech, Inc.
Oct 23, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
Apr 16, 2025Janssen Biotech, Inc.
Apr 16, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
Oct 23, 2025Janssen Biotech, Inc.
Oct 23, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
May 20, 2025Pfizer Inc.
May 20, 2025
Consulting Fee$3,050
May 15, 2025Astellas Pharma US Inc
May 15, 2025
Consulting Fee
Padcev · Oncology
$3,000
May 12, 2025Ferring Pharmaceuticals Inc.
May 12, 2025
Consulting Fee
ADSTILADRIN · ONCOLOGY
$2,850
Dec 3, 2025Immunitybio, Inc.
Dec 3, 2025
Honoraria
ANKTIVA · Immunotherapy
$2,500
Aug 15, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 15, 2025
Compensation for services other than consulting (speaking, faculty)
Nubeqa · Oncology
$1,470
All 35 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 23, 2025Dendreon Pharmaceuticals LLC
Dec 23, 2025
Compensation for services other than consulting (speaking, faculty)
PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER
$1,400
Dec 17, 2025Merck Sharp & Dohme LLC
Dec 17, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$4,770
Dec 10, 2025Merck Sharp & Dohme LLC
Dec 10, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Denver, CO · in-kind
$296
Dec 10, 2025Merck Sharp & Dohme LLC
Dec 10, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Denver, CO · in-kind
$176
Dec 3, 2025Immunitybio, Inc.
Dec 3, 2025
Honoraria
ANKTIVA · Immunotherapy
$2,500
Nov 26, 2025Dendreon Pharmaceuticals LLC
Nov 26, 2025
Compensation for services other than consulting (speaking, faculty)
PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER
$1,400
Nov 24, 2025Janssen Scientific Affairs, LLC
Nov 24, 2025
Consulting Fee
ERLEADA · Oncology
$1,410
Nov 19, 2025Janssen Pharmaceuticals, Inc
Nov 19, 2025
Consulting Fee$1,410
Nov 17, 2025Pfizer Inc.
Nov 17, 2025
Consulting Fee$610
Nov 5, 2025Astellas Pharma US Inc
Nov 5, 2025
Consulting Fee
Xtandi · Oncology
$5,000
Oct 28, 2025Janssen Biotech, Inc.
Oct 28, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to Joplin, MO · in-kind
$1,034
Oct 23, 2025Janssen Biotech, Inc.
Oct 23, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
Oct 23, 2025Janssen Biotech, Inc.
Oct 23, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
Oct 13, 2025Janssen Biotech, Inc.
Oct 13, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to Joplin, MO · in-kind
$5.50
Sep 2, 2025Pfizer Inc.
Sep 2, 2025
Consulting Fee$1,220
Sep 2, 2025Pfizer Inc.
Sep 2, 2025
Consulting Fee$610
Aug 15, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 15, 2025
Compensation for services other than consulting (speaking, faculty)
Nubeqa · Oncology
$1,470
Jul 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 3, 2025
Compensation for services other than consulting (speaking, faculty)
Nubeqa · Oncology
$1,470
Jul 2, 2025Janssen Biotech, Inc.
Jul 2, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$1,110
May 29, 2025Janssen Biotech, Inc.
May 29, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$694
May 21, 2025Janssen Biotech, Inc.
May 21, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$416
May 20, 2025Pfizer Inc.
May 20, 2025
Consulting Fee$3,050
May 15, 2025Astellas Pharma US Inc
May 15, 2025
Consulting Fee
Padcev · Oncology
$3,000
May 12, 2025Ferring Pharmaceuticals Inc.
May 12, 2025
Consulting Fee
ADSTILADRIN · ONCOLOGY
$2,850
Apr 16, 2025Janssen Biotech, Inc.
Apr 16, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$4,163
Apr 16, 2025Janssen Biotech, Inc.
Apr 16, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to Overland Park, KS
$252
Apr 11, 2025Janssen Biotech, Inc.
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$1,110
Apr 11, 2025Janssen Biotech, Inc.
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$1,110
Apr 11, 2025Janssen Biotech, Inc.
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$1,110
Apr 2, 2025Janssen Biotech, Inc.
Apr 2, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to Omaha, NE · in-kind
$5.50
Mar 27, 2025Janssen Biotech, Inc.
Mar 27, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to Omaha, NE · in-kind
$5.50
Mar 17, 2025Dendreon Pharmaceuticals LLC
Mar 17, 2025
Compensation for services other than consulting (speaking, faculty)
PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER
$1,050
Mar 15, 2025Bayer HealthCare Pharmaceuticals Inc.
Mar 15, 2025
Compensation for services other than consulting (speaking, faculty)
Nubeqa · Oncology
$1,470
Mar 12, 2025Janssen Biotech, Inc.
Mar 12, 2025
Travel and Lodging
RYBREVANT; CARVYKTI · Oncology · travel to KANSAS CITY, MO · in-kind
$5.50
Feb 26, 2025Janssen Biotech, Inc.
Feb 26, 2025
Compensation for services other than consulting (speaking, faculty)
RYBREVANT; CARVYKTI · Oncology
$555

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kansas →

Industry-funded research

Named as a principal investigator on 16 industry-funded studies in 2025, from 6 companies. The companies reported $1,011,167 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
    Janssen Research & Development, LLC
  • A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
    Janssen Research & Development, LLC
  • A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
    Janssen Research & Development, LLC
  • MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-…
    Janssen Research & Development, LLC
  • A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
    Merck Sharp & Dohme LLC
  • A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
    Sumitomo Pharma America, Inc. · Completed · NCT05467176
  • A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
    Janssen Research & Development, LLC
  • A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
    Janssen Research & Development, LLC
  • A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutam…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Wichita

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 10, 2012), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1508985417. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.